Stay updated on Propranolol and Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the Propranolol and Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange Detected- Added a government funding lapse notice and current operating status guidance for NIH Clinical Center, and a version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check31 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0 with removal of two medical terms; adds a new version label and slightly reclassifies content.SummaryDifference0.2%

- Check45 days agoChange DetectedUpdated version from v3.0.1 to v3.0.2 and removed the Back to Top link; no other substantive content changes.SummaryDifference0.2%

- Check52 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new pharmaceutical terms and classifications. Notably, the previous version's details on propranolol hydrochloride have been removed, indicating a shift in focus.SummaryDifference4%

- Check74 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%

Stay in the know with updates to Propranolol and Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Propranolol and Pembrolizumab in Melanoma Clinical Trial page.